drugset / Trial / NCT03013751

A Extension Study of Udenafil in Adolescents

NCT03013751

NaSingle-groupOpen-labelTreatment

Summary

This study is a 12-month (52 week) safety extension study to supplement the FUEL Phase III clinical trial to provide safety information regarding the long-term use of udenafil in adolescents with single ventricle congenital heart disease.

Timeline

Start
2017-02-06
Primary completion
2019-12-30
Completion
2022-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Udenafil Small molecule